{"id":51627,"date":"2026-06-28T16:52:09","date_gmt":"2026-06-28T14:52:09","guid":{"rendered":"https:\/\/prizrenpost.com\/tr\/tip-1-diyabeti-yillarca-geciktirebilecek-devrim-niteligindeki-ilac\/"},"modified":"2026-06-28T16:52:10","modified_gmt":"2026-06-28T14:52:10","slug":"tip-1-diyabeti-yillarca-geciktirebilecek-devrim-niteligindeki-ilac","status":"publish","type":"post","link":"https:\/\/prizrenpost.com\/tr\/tip-1-diyabeti-yillarca-geciktirebilecek-devrim-niteligindeki-ilac\/","title":{"rendered":"Tip 1 diyabeti y\u0131llarca geciktirebilecek devrim niteli\u011findeki ila\u00e7"},"content":{"rendered":"

<\/p>\n

Tip 1 diyabetin ba\u015flang\u0131c\u0131n\u0131 geciktiren devrim niteli\u011finde bir ilac\u0131n, \u0130ngiltere ve Galler halk sa\u011fl\u0131\u011f\u0131 sisteminde (NHS) kullan\u0131lmas\u0131 onayland\u0131. Bu, “The Guardian”a g\u00f6re hastal\u0131\u011f\u0131n tedavisinde bir y\u00fczy\u0131ldan fazla s\u00fcredir yap\u0131lan en b\u00fcy\u00fck at\u0131l\u0131md\u0131r.<\/p>\n

Teplizumab (ticari ad\u0131 Tzield) olarak adland\u0131r\u0131lan ila\u00e7, tip 1 diyabeti iyile\u015ftirmez ancak semptomatik geli\u015fimini \u00fc\u00e7 y\u0131la kadar geciktirebilir.<\/p>\n

Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini sald\u0131rmamak i\u00e7in ‘e\u011fiterek’ \u00e7al\u0131\u015f\u0131r. ins\u00fclin \u00fcreten pankreas h\u00fccreleri.<\/p>\n

Ulusal Sa\u011fl\u0131k ve Bak\u0131m M\u00fckemmeliyeti Enstit\u00fcs\u00fc (NICE), ilac\u0131n tip 1 diyabetin erken, semptomsuz a\u015famas\u0131ndaki yeti\u015fkinlerde ve 8 ya\u015f\u0131n \u00fczerindeki \u00e7ocuklarda kullan\u0131lmas\u0131n\u0131 onaylad\u0131.<\/p>\n

Uzmanlar, bunun hastalara kal\u0131c\u0131 ins\u00fclin tedavisine ihtiya\u00e7 duymadan \u00f6nce de\u011ferli y\u0131llar kazand\u0131rd\u0131\u011f\u0131n\u0131 s\u00f6yl\u00fcyor.<\/p>\n

Teplizumab, art arda 14 g\u00fcn boyunca g\u00fcnde bir kez intraven\u00f6z inf\u00fczyon yoluyla uygulan\u0131r. \u0130ki haftal\u0131k k\u00fcr\u00fcn ard\u0131ndan tedavi ba\u015fka doza gerek kalmadan kapat\u0131l\u0131yor.<\/p>\n

“Diabetes UK” adl\u0131 yard\u0131m kurulu\u015funa g\u00f6re, bu ilac\u0131n onaylanmas\u0131 tip 1 diyabet tedavisinde yeni bir d\u00f6nemin ba\u015flang\u0131c\u0131n\u0131 i\u015faret ediyor. \u00c7\u00fcnk\u00fc 100 y\u0131l\u0131 a\u015fk\u0131n s\u00fcredir ilk kez t\u0131p ins\u00fclinin \u00f6tesine ge\u00e7iyor ve hastal\u0131\u011f\u0131n alt\u0131nda yatan nedeni hedef al\u0131yor.<\/p>\n

Uzmanlar, \u00f6zellikle \u00e7ocuklar ve ergenler olmak \u00fczere hastalara, Diyabet y\u00f6netiminin g\u00fcnl\u00fck y\u00fck\u00fcnden kurtulmak i\u00e7in daha fazla zaman.<\/p>\n

\n

Kaynak: prizrenpost<\/strong><\/p>\n","protected":false},"excerpt":{"rendered":"

Tip 1 diyabetin ba\u015flang\u0131c\u0131n\u0131 geciktiren devrim niteli\u011finde bir ilac\u0131n, \u0130ngiltere ve Galler halk sa\u011fl\u0131\u011f\u0131 sisteminde (NHS) kullan\u0131lmas\u0131 onayland\u0131. Bu, “The Guardian”a g\u00f6re hastal\u0131\u011f\u0131n tedavisinde bir y\u00fczy\u0131ldan fazla s\u00fcredir yap\u0131lan en b\u00fcy\u00fck at\u0131l\u0131md\u0131r. Teplizumab (ticari ad\u0131 Tzield) olarak adland\u0131r\u0131lan ila\u00e7, tip 1 diyabeti iyile\u015ftirmez ancak semptomatik geli\u015fimini \u00fc\u00e7 y\u0131la kadar geciktirebilir. Ba\u011f\u0131\u015f\u0131kl\u0131k sistemini sald\u0131rmamak i\u00e7in ‘e\u011fiterek’ […]<\/p>\n","protected":false},"author":1,"featured_media":51628,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[5],"tags":[],"class_list":["post-51627","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-saglik"],"views":3,"_links":{"self":[{"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/posts\/51627","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/comments?post=51627"}],"version-history":[{"count":1,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/posts\/51627\/revisions"}],"predecessor-version":[{"id":51629,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/posts\/51627\/revisions\/51629"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/media\/51628"}],"wp:attachment":[{"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/media?parent=51627"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/categories?post=51627"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/prizrenpost.com\/tr\/wp-json\/wp\/v2\/tags?post=51627"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}